Pyxis Oncology (PYXS) Other Accumulated Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Other Accumulated Expenses data on file, last reported at $4.0 million in Q4 2025.

• Other Accumulated Expenses for Q4 2025 came in at $4.0 million, down 37.2% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.0 million (down 37.2% YoY), and the FY2025 annual result was $4.0 million, down 37.2% from the prior year.
• Other Accumulated Expenses fell to $4.0 million in Q4 2025 per PYXS's latest filing, from $6.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $17.4 million in Q4 2022 and troughed at $2.4 million in Q4 2021.
• A 5-year average of $7.4 million and a median of $6.4 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses surged 631.37% in 2022, then slumped 62.13% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $2.4 million in 2021, then surged by 631.37% to $17.4 million in 2022, then tumbled by 62.13% to $6.6 million in 2023, then fell by 3.47% to $6.4 million in 2024, then sank by 37.2% to $4.0 million in 2025.
• Business Quant data shows PYXS's Other Accumulated Expenses at $4.0 million in Q4 2025, $6.4 million in Q4 2024, and $6.6 million in Q4 2023.